UPLC1/ASAP3 Antibody
Anti-UPLC1/ASAP3 Antibody - Western Blot
Datasheet is currently unavailable. Try again or CONTACT US

UPLC1/ASAP3 Antibody

Rabbit Polyclonal

100 µg
Have a Question? Ask a Specialist
$399.00 /Per Item
Availability: Ships next business day
Shipping info:

$50.00 to US & Canada for most products. Final costs are calculated at checkout.



This antibody is designed, produced, and validated as part of a collaboration between Rockland and the National Cancer Institute (NCI) and is suitable for Cancer, Immunology and Nuclear Signaling research. Anti-UPLC1 (up-regulated in liver cancer 1) / ASAP3 Antibody, also named DDEFL1 (development and differentiation-enhancing factor-like 1) or ASAP3, is a member of the AZAP family of proteins. These proteins catalyze the hydrolysis of GTP bound to ADP-ribosylation factor (Arf) proteins, thereby causing Arf inactivation. For this reason, the ASAPs are generally called ArfGAPs.  The activity of ArfGAPs is dependent on the presence of phosphoinositides and is implicated in cellular processes such as membrane trafficking and remodeling of the actin cytoskeleton.  ASAP3 has been found to be up-regulated in 80% of the hepatocellular carcinomas examined.  Initial biochemical characterization reveals that ASAP3 shows class-specific GAP activity on Arf proteins, preferring Arf5 over Arf1 and Arf6. ASAP3 antibody has beed developed through the NCI antibody collaboration program and is ideal for Cancer and Signal Transduction research.

Application Note

This protein A purified antibody has been tested for use in ELISA and western blotting.  Specific conditions for reactivity should be optimized by the end user.  Expect a band approximately 100 kDa in size corresponding to UPLC1/ASAP3 protein by western blotting in the appropriate cell lysate or extract.


This protein A purified antibody is directed against human UPLC1/ASAP3 protein.  The product was purified from monospecific antiserum by protein A chromatography.  A BLAST analysis was used to suggest cross-reactivity with UPLC1/ASAP3 protein from mouse and rat based on approximately 80% homology with the human protein.  Reactivity against homologues from other sources is not known.

Anti-UPLC1/ASAP3 (RABBIT) Antibody - 200-401-990
rabbit anti-UPLC1 Antibody, rabbit anti-ASAP3 Antibody, UPLC1/ASAP3 Antibody, Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 3, FLJ20199 antibody, Gm140 antibody, Development and differentiation-enhancing factor-like 1, Protein up-regulated in liver cancer 1, DDEFL1
Recombinant Protein
This antibody was prepared from whole rabbit serum produced by repeated immunizations with recombinant human UPLC1/ASAP3 protein.
Liquid (sterile filtered)
1.10 mg/mL
0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
0.01% (w/v) Sodium Azide
Dry Ice
Store UPLC1 / ASAP3 Antibody at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
Expiration date is one (1) year from date of opening.
Luo Y et al. Loss of ASAP3 destabilizes cytoskeletal protein ACTG1 to suppress cancer cell migration. Mol Med Rep. (2014)

Invalid lot number

If you need help finding your CofA, contact us

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.